The current status of targeted therapy for non-small cell lung cancer

Internal Medicine Journal

Volumn 40, Issue 9, 2010, Pages 611-618

  Francis, H ^a   Solomon, B ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

epidermal growth factor receptor; erlotinib; gefitinib; non small cell lung cancer; targeted therapy; vascular endothelial growth factor

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; AFLIBERCEPT; ANTIBIOTIC AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIGITUMUMAB; GEFITINIB; MINOCYCLINE; MOTESANIB; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NAVELBINE; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PEMETREXED; PF 299804; SORAFENIB; STEROID; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ACNE; ANTIBIOTIC THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASIAN; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DISEASE CONTROL; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; DRY SKIN; ETHNICITY; FEBRILE NEUTROPENIA; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LUNG ADENOCARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR GENE; REVIEW; SKIN INFECTION; SKIN MANIFESTATION; TOPICAL TREATMENT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77956801719     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.02141.x     Document Type: Review

References (46)

1. AIHW (Australian Institute of Health and Welfare) and AACR (Australasian Association of Cancer Registries). Cancer in Australia: An Overview, 2008. Cancer series no. 46. Cat. no. CAN 42.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
3. Ridolfo B, Stevenson C. The quantification of drug-caused mortality and morbidity in Australia, 1998. AIHW Cat. No. PHE 29.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995 311 : 899 909.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002 346 : 92 8.
6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 22 : 1589 97.
7. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000 18 : 2095 103.
8. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008 358 : 1160 74.
9. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003 21 : 2237 46.
10. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D, Belani CP et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 290 : 2149 58.
11. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D et al. Determinants of tumor response and survival with erlotinib in patients with non - small-cell lung cancer. J Clin Oncol 2004 22 : 3238 47.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 353 : 123 32.
13. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005 366 : 1527 37.
14. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008 372 : 1809 18.
15. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F et al. Phase III study of Erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007 25 : 1545 52.
16. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V et al. Gefitinib in combination with gemcitabine and cisplatin in Advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004 22 : 777 84.
17. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004 22 : 785 94.
18. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005 23 : 5892 99.
19. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009 373 : 1525 31.
20. Lynch T, Patel T, Dreisbach L, McCleod M, Heim WJ, Robert H et al. A randomized multicenter phase III study of cetuximab (Erbitux[R]) in combination with taxane/carboplatin versus taxane/carboplatin alone as first-line treatment for patients with advanced/metastatic non-small cell lung cancer (NSCLC): BMS 099. J Thorac Oncol 2007 2 (Suppl 8 S340 1.
21. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 361 : 947 57.
22. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005 97 : 643 55.
23. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350 : 2129 39.
24. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 : 1497 500.
25. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 101 : 13306 11.
26. Jackman DM, Miller VA, Cioffredi L-A, Yeap BY, Janne PA, Riely GJ et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009 15 : 5267 73.
27. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008 359 : 366 77.
28. Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007 99 : 838 46.
29. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005 2 : e73.
30. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 316 : 1039 43.
31. Lynch TJ Jr., Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007 12 : 610 21.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 : 57 70.
33. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971 285 : 1182 6.
34. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 22 : 2184 91.
35. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 355 : 2542 50.
36. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008 26 : 60 5.
37. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009 27 : 1227 34.
38. De Boer R, Arrieta Ó, Gottfried M, Blackhall FH, Raats J, Yang CH et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009 27 (Suppl. S15 (abstract 8010).
39. Herbst RS, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 2009 27 (Suppl. S18 (abstract CRA8003).
40. Blumenschein GR Jr., Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009 27 : 4274 80. JCO.2009.22.0541.
41. Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008 3 : 815 18.
42. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 2009 27 : 2516 22.
43. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 448 : 561 6.
44. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 27 : 4247 53. JCO.2009.22.6993.
45. Kwak EL, Camidge DR, Clark J, Shapiro GI, Maki RG, Ratain MJ et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009 27 (Suppl. S15 (abstract 3509).
46. Flaherty K, Puzanov I, Sosman J, Kim K, Ribas A, McArthur G et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009 27 (Suppl. S15 (abstract 9000).